Latest News

The public feud between President Trump and the central bank may be heating up.

Palantir has a lot of growth priced into its stock.

The consumer tech leader has been a winning investment over the long term.

CapsoVision (NASDAQ:CV) outlined its strategy to expand capsule endoscopy technology beyond its current small-bowel business into colon, pancreatic and esophageal cancer screening applications, highlighting its artificial intelligence capabilities, cloud-based workflow and upcoming regulatory submis

AI has a storage problem. That gives Seagate a role investors should understand.

Pfizer has a plan to bounce back from recent obstacles.

Lexeo Therapeutics (NASDAQ:LXEO) outlined its approach to evaluating LX2020, an investigational AAVrh10-based gene therapy for PKP2-associated arrhythmogenic cardiomyopathy, or ACM, ahead of an expected clinical and regulatory update later this quarter. CEO Nolan Townsend said PKP2 ACM is a serious

Just a few months ago, they were shorting it.

Space Exploration Technologies' stock price is rallying after earnings, but the most meaningful gains for shareholders won't come from just one quarterly report.

$4.5 billion in available capital gives management flexibility to fund growth and return cash to shareholders as freight conditions stabilize.

If you are a long-term investor with 10 to 20 years ahead of you, there's a good chance you will run into a market crash at some point.

BlockchAIn Digital Infrastructure (NYSEAMERICAN:AIB) outlined a data-center development strategy centered on smaller, power-secured facilities, long-term tenant contracts and project-level financing during a presentation by CFO Jolienne Halisky. Halisky said the company views itself as a “right-siz

OpenAI dialed back its initial aim for a $1.5 trillion.

XRP has already gone parabolic three times. Here's how it could happen yet again.

Sales growth is only part of the story for one of the leading AI labs, which is expected to go public this year.

You can't go wrong with either, but one seems to have more runway.

Kits Eyecare (TSE:KITS) is targeting further growth in the online optical market by expanding its higher-margin glasses business, increasing brand awareness through select physical locations and leveraging a manufacturing operation that management says has substantial unused capacity. Speaking at a

Has the AI boom already peaked?

Vertex Pharmaceuticals (NASDAQ:VRTX) outlined updates across its kidney disease pipeline at the American Society of Nephrology Kidney Week 2026, highlighting data for povetacicept in IgA nephropathy and inaxaplin in APOL1-mediated kidney disease, or AMKD. Chief Executive Officer and President Reshm

SpaceX delivered a stronger quarter than I expected. But its accelerating AI spending leaves shareholders with a very expensive question.

Novartis (NYSE:NVS) presented Phase III results for remibrutinib in relapsing multiple sclerosis, reporting that the oral Bruton’s tyrosine kinase inhibitor reduced relapse rates and MRI lesion activity versus teriflunomide in the REMODEL-1 and REMODEL-2 studies. The company said global regulatory

Analyze the current issues impacting data centres, from AI investment strategies to concerns reminiscent of past financial crises.

Canadian utility stocks report soon. See what Fortis, Emera and Canadian Utilities investors should consider before buying ahead of earnings.